Tanvex BioPharma Inc banner

Tanvex BioPharma Inc
TWSE:6541

Watchlist Manager
Tanvex BioPharma Inc Logo
Tanvex BioPharma Inc
TWSE:6541
Watchlist
Price: 48.1 TWD -1.84% Market Closed
Market Cap: NT$12.7B

Tanvex BioPharma Inc
Investor Relations

Tanvex BioPharma, Inc. operates as clinical stage company, which engages in the research and development, production, and sale of pharmaceutical products. The firm is also engaged in areas of strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing and warehousing, sales and distribution. The Company’s product pipeline includes Neupogen (TX-01), TX-05, TX-04, TX-16, TX-52, and others. The firm offers a vertically integrated manufacturing platform for biopharmaceuticals. By controlling the entire process from research and development (R&D) and cell-line development. The firm is developing and delivering biologic and biosimilar drugs to the people.

Show more
Loading
6541
Taiwan Weighted Index
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Stephen Lam
Chief Executive Officer
No Bio Available
Dr. Allen Y. Chao Ph.D.
Founder & Honorary Chairman
No Bio Available
Val Chen
VP of Finance Director of Ops. Mgmt., Corporate Governance Officer & Chief Internal Auditor
No Bio Available
Mr. James Williamson
Accounting Officer
No Bio Available
Mr. Zheng Xia
Chief Technology Officer
No Bio Available
Linda Grillo
Director of Sales & Marketing
No Bio Available
Hsun-Chiang Hsieh
Secretary
No Bio Available

Contacts

Address
George Town
Floor 4, Willow House, Cricket Square, P O BOX 2804
Contacts